Last reviewed · How we verify
A197 Ophthalmic Solution
A197 Ophthalmic Solution is a topical corticosteroid used to reduce inflammation in the eye.
A197 Ophthalmic Solution is a topical corticosteroid used to reduce inflammation in the eye. Used for Treatment of inflammation and pain in the eye.
At a glance
| Generic name | A197 Ophthalmic Solution |
|---|---|
| Sponsor | Aramis Biosciences, Inc. |
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
A197 Ophthalmic Solution works by inhibiting the production of inflammatory mediators in the eye, thereby reducing swelling and pain. This is achieved through the action of its active ingredient, which is a corticosteroid. Corticosteroids are a class of steroid hormones that are produced by the adrenal gland and play a crucial role in regulating inflammation in the body.
Approved indications
- Treatment of inflammation and pain in the eye
Common side effects
- Eye irritation
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A197 Ophthalmic Solution CI brief — competitive landscape report
- A197 Ophthalmic Solution updates RSS · CI watch RSS
- Aramis Biosciences, Inc. portfolio CI